Research Intelligence
for Peptides & Compounds

Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.

A 22-patient randomized sarcoidosis pilot reported improvement in the small-fiber neuropathy screening score, but pain and fatigue scores improved similarly in both groups.

ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density.

A blinded placebo-controlled sarcoidosis study reported improved neuropathic symptoms and corneal nerve-fiber density after 28 days; the findings remain exploratory.

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

An early controlled phase 2 study in type 2 diabetes with painful neuropathy reported metabolic and neuropathic symptom signals over 56 days, with subgroup nerve-fiber findings.